SARS-CoV-2 and immunology: antibody developments
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
List view / Grid view
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
Researchers have uncovered a flaw in lab models used to study the human blood-brain barrier and a potential strategy to correct the error.
The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
Researchers have suggested that dormant HIV can be eradicated from cells by attacking it based on its viral activities.
A new MVA-based vaccine has shown success at inducing COVID-19 antibody and T-cell responses in pre-clinical studies.
Using a mouse model, researchers found that cancer progression led to fewer skeletal muscle ribosomes, likely explaining muscle wasting.
Researchers have found that SARS-CoV-2 evades immune responses by deleting parts of its genetic sequence that encode for the Spike protein.
A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
A study using stem cells has revealed that DCM-causing mutations in LMNA disrupt the organisation of DNA in the nucleus of heart muscle cells.
Researchers have discovered that two enzymes called APOBEC3C and ADAR1 work together to fuel the transition from pre-cancer stem cells to cancer stem cells in leukaemia.
A team has used their new organs-on-a-chip system to replicate the interactions between the brain, liver and colon.
Researchers have developed a new mass spectrometer that uses rotation frequencies of ionised molecules to measure mass with high accuracy.
A study has found that T cells combat SARS-CoV-2 by targeting many sites on the coronavirus, not just the Spike protein.
Researchers have found a druggable insulin inhibitory receptor named inceptor that could provide a drug target for diabetes.